Farxiga is not a GLP-1. It belongs to a completely different drug class called SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors). While both Farxiga and GLP-1 drugs like semaglutide are used for type 2 diabetes, they work through entirely different mechanisms in the body and have distinct strengths.
How Farxiga Works
Farxiga (dapagliflozin) lowers blood sugar by changing what happens in your kidneys. Normally, your kidneys filter glucose out of the blood and then reabsorb most of it back into the bloodstream. Farxiga blocks the protein responsible for that reabsorption, so more glucose leaves your body through urine instead of cycling back into your blood. This process works independently of insulin, meaning it doesn’t depend on how well your pancreas is functioning or how sensitive your cells are to insulin.
How GLP-1 Drugs Work Differently
GLP-1 receptor agonists take a completely different approach. They mimic a gut hormone that suppresses appetite, slows stomach emptying, and reduces food consumption. The result is that you eat less and your blood sugar rises more gradually after meals. Popular GLP-1 drugs include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound).
The easiest way to think about it: Farxiga removes excess sugar through your kidneys, while GLP-1 drugs reduce how much food and sugar enter your system in the first place.
Weight Loss: A Notable Gap
Both drug classes cause weight loss, but the scale is quite different. In clinical studies, Farxiga typically produces modest weight loss of about 2.5 to 4.5 kilograms (roughly 5 to 10 pounds) over several months to two years. One study of people with type 2 diabetes taking 10 mg daily for 102 weeks found an average loss of 4.54 kg, along with a 5 cm reduction in waist circumference.
GLP-1 drugs, particularly newer ones like semaglutide, routinely produce significantly more weight loss, often in the range of 10 to 15 percent of body weight. If weight loss is your primary goal, Farxiga and GLP-1s are not in the same category.
Where Farxiga Excels: Heart and Kidney Protection
Farxiga has carved out a unique role in protecting the heart and kidneys, with FDA approvals that go well beyond blood sugar control. It is currently approved for four uses:
- Chronic kidney disease at risk of progression, to slow kidney decline and reduce the risk of kidney failure and cardiovascular death
- Heart failure (regardless of diabetes status), to reduce hospitalizations and cardiovascular death
- Type 2 diabetes with cardiovascular disease or high cardiovascular risk, to reduce heart failure hospitalizations
- Type 2 diabetes as an add-on to diet and exercise for blood sugar control
The kidney data is especially striking. In the landmark DAPA-CKD trial, Farxiga reduced the combined risk of worsening kidney function, end-stage kidney disease, and cardiovascular or kidney-related death by 39% compared to placebo over a median of 2.4 years. It also reduced death from any cause by 31%. Notably, these benefits applied to people with chronic kidney disease whether or not they had diabetes.
Side Effects Compared
The two drug classes cause different types of side effects, which often matters when choosing between them. The most common serious side effects of SGLT2 inhibitors like Farxiga are genital yeast infections (particularly in women) and, rarely, a condition called diabetic ketoacidosis, where acid builds up in the blood even when blood sugar levels appear normal. Increased urination is also common, since the drug works by flushing glucose through the kidneys.
GLP-1 drugs, by contrast, are best known for gastrointestinal side effects: nausea, vomiting, and stomach upset, especially during the first weeks as your body adjusts. For people who already struggle with digestive issues, this distinction can be a deciding factor.
How You Take Them
Farxiga is a once-daily pill. Most GLP-1 drugs are injections, given either daily or weekly depending on the specific medication. Oral semaglutide (Rybelsus) is an exception, but the majority of GLP-1 options still require a needle. For people who prefer not to inject, Farxiga’s pill form is a practical advantage.
When Doctors Choose One Over the Other
Current guidelines from the American Diabetes Association treat SGLT2 inhibitors and GLP-1 drugs as complementary tools rather than competitors. The choice depends largely on what else is going on in your body beyond blood sugar.
For people with heart failure, SGLT2 inhibitors like Farxiga are specifically recommended to prevent hospitalizations, whether the heart’s pumping ability is reduced or preserved. For chronic kidney disease with moderate kidney function decline, either an SGLT2 inhibitor or GLP-1 drug can be appropriate. But when kidney function drops very low, GLP-1 drugs are generally preferred for blood sugar management because they carry a lower risk of hypoglycemia in that setting.
GLP-1 drugs get the nod for people with liver disease related to fat buildup (sometimes called metabolic liver disease), and they tend to be prioritized when significant weight loss is a treatment goal. For people with atherosclerotic cardiovascular disease, such as a history of heart attack or stroke, guidelines recommend either class or both together.
In many cases, the two drugs complement each other well enough that some people take both. They work through completely separate pathways, so combining them can address blood sugar, weight, heart health, and kidney protection simultaneously.